T-cell lymphoma

rdf:langString T-cell lymphoma

rdf:langString T-cell lymphoma

rdf:langString T-cell lymphoma

rdf:langString

rdf:langString ,

rdf:langString C84.

rdf:langString C86.

rdf:langString D016399

rdf:langString swollen lymph nodes, fevers, enlarged liver or spleen, liver dysfunction, rash

rdf:langString Micrograph of an enteropathy-associated T-cell lymphoma , a type of T-cell lymphoma. H&E stain.

rdf:langString September 2022

rdf:langString Hematology and oncology

rdf:langString incidence is normally used only in the singular form, perhaps incidence, incidents, or instances was intended

rdf:langString T-cell lymphoma is a rare form of cancerous lymphoma affecting T-cells. Lymphoma arises mainly from the uncontrolled proliferation of T-cells and can become cancerous. T-cell lymphoma is categorized under Non-Hodgkin lymphoma (NHL) and represents less than 15% of all Non-Hodgkin's diseases in the category. T-cell lymphomas are often categorised based on their growth patterns as either; aggressive (fast-growing) or indolent (slow-growing). Although the cause of T-cell lymphoma is not definitive, it has been associated with various risk factors and viruses such as Epstein–Barr virus (EBV) and Human T-cell leukemia virus-1 (HTLV1). The prognosis and treatment of T-cell lymphoma can vary drastically based on the specific type of lymphoma and its growth patterns. Due to their rarity and high variability between the different subtypes, the prognosis of T-cell lymphoma is significantly worse than other Non-Hodgkin lymphoma. The treatment of T-cell lymphoma is often similar to other Non-Hodgkin lymphomas with early-stage treatments consisting of chemotherapy and/or radiology. The effectiveness of these treatments is often varied between subtypes with most receiving a poor outcome with high relapse rates.